Patents for A61P 35 - Antineoplastic agents (221,099)
07/2008
07/22/2008US7403805 Apparatus and method for noninvasive measurement of analytes from the conjunctiva using mid-infrared radiation
07/22/2008US7402727 Model produced by injecting an immunodeficient mouse with a suspension of single cells of human small cell lung carcinoma SBC-5 cells to effect metastasis in the mouse's own bone; used for screening anticancer drugs
07/22/2008US7402688 novel 2,2-disubstituted-19-norvitamin D derivatives and 20-epi-19-norvitamin D derivatives; metabolic regulatory hormone of calcium and phosphorus; biological activities: cellular induced differentiation, suppression of proliferation, and immunomodulation by transcription control of target gene
07/22/2008US7402682 affinity for peripheral-type benzodiazepine receptors; in vitro and in vivo affinity; chemical intermediates
07/22/2008US7402660 Inhibiting neoangiogenesis by administering a molecule with an antibody variable region which specifically binds to an extracellular domain of a TEM protein
07/22/2008US7402658 TRAIN-R: a cysteine-rich member of the TNF-receptor family
07/22/2008US7402657 C-C chemokine receptor 3 proteins
07/22/2008US7402655 Nucleotide sequences coding polypeptide for use in the treatment of canccer, inflamation and infectious disorders
07/22/2008US7402611 Use of amino acids for making medicines for treating to insulin-resistance
07/22/2008US7402605 E.g., 17,17-propano-16-hydroxy-5-(4-ethoxycarbonylthiazol-2-yl)-9-oxo-1,2,3,4,20-pentanor-5-thia-8-azaprost-13-ene; EP2 and/or EP4 receptor agonist; immune disease; antiallergens; alopecia; dysmenorrhea; erectile dysfuncction; antiarthritic agents; liver, respiratory, vascular, urogenital disorder
07/22/2008US7402603 Cyclooxygenase-2 inhibitor/histone deacetylase inhibitor combination
07/22/2008US7402597 e.g. [[7-Allyl-3-[2-[2-(2,4-dichlorophenyl)-5-isopropyl-4-oxazolyl]ethyl]-1,2-benzisoxazol-6-yl]oxy]acetic acid; with vehicles (lactose, D-mannitol, glucose), disintegrators (starch or carboxymethylcellulose calcium ), binders (hydroxypropylcellulose) and lubricants (magnesium stearate or talc)
07/22/2008US7402595 JNK inhibitor
07/22/2008US7402585 For example, 2-(3-{[6-methoxy-7-(3-morpholin-4-ylpropoxy)quinazolin-4-yl]amino}-1H-pyrazol-5-yl)-N-phenylacetamide; use in the treatment of certain diseases, in particular to proliferative disease such as cancer
07/22/2008US7402583 Substituted quinolines as antitumor agents
07/22/2008US7402577 Androstane 17-beta-carboxamides as androgen receptor modulators
07/22/2008US7402572 Suppressing a symptom of an allergic response using nucleic acids containing unmethylated CpG dinucleotides
07/22/2008US7402569 Combining such as sulforaphane with glucosinolate component; economical food additive or dietary supplement
07/22/2008US7402563 EPF derived peptides and therapeutic compositions
07/22/2008US7402557 Reducing epithelial toxicity such as a skin rash or diarrhea during cancer therapy, by coadministering KGF with erlotinib (N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazoline amine)
07/22/2008US7402427 Genomic RNA of paramyxovirus encoding M and F proteins; decreased production of viral particles; suppresses cancer growth
07/22/2008US7402421 Recombinant methods and materials for producing epothilone and epothilone derivatives
07/22/2008US7402394 Screening for compound that activates or inhibits activity of Aster Associated Protein; over-expression disrupts mitotic spindle assembly and leads to aberrant and abortive mitosis
07/22/2008US7402388 Using immunophilin (FKBP54) expression as diagnostic/prognostic indicator of cell proliferative disorders; antitumor agents
07/22/2008US7402324 Process for preparing aqueous extracts of plants and extracts so obtained
07/22/2008US7402317 Culturing human cancer cells; purification, recovering of antigens
07/22/2008US7402314 Antigen peptides; medical diagnosis
07/22/2008US7402306 Cancer immunotherapy with semi-allogeneic cells
07/22/2008US7402305 Comprises nucleotide sequences coding protein with antiproliferative and viricidal activity for use in treatment and prevention of cancer, nervous system, bone and autoimmune disorders
07/22/2008US7402304 human granulocyte colony stimulating factor polypeptides having amino acid replacements in the sequence, used for treating hematopoietic, neurological or reproductive disorders
07/22/2008US7402299 Intracorporeal medicaments for photodynamic treatment of disease
07/22/2008CA2481246C Compounds that modulate ppar activity and methods for their preparation
07/22/2008CA2474511C Benzofuran and benzothiophene derivatives useful in the treatment of hyper-proliferative disorders
07/22/2008CA2457056C Pharmaceutical compositions comprising polysaccharide conjugates for inhibiting the metastasis or preventing the recurrence of malignant tumor
07/22/2008CA2436942C Method of manufacturing substance gm-95
07/22/2008CA2384418C Use of cytokines, cells, and mitogens to inhibit graft versus host disease
07/22/2008CA2383011C Therapeutic uses of polymers and oligomers comprising gamma-hydroxybutyrate
07/22/2008CA2372840C Substituted bicyclic compounds
07/22/2008CA2368614C Improved cancer treatment with temozolomide
07/22/2008CA2310748C Substituted 11-phenyl-dibenzazepine compounds useful for the treatment or prevention of diseases characterized by abnormal cell proliferation
07/22/2008CA2289017C The use of a nitroxide or a prodrug thereof in the prophylactic and therapeutic treatment of cancer
07/22/2008CA2282706C Adenovirus vectors specific for cells expressing .alpha.-fetoprotein and methods of use thereof
07/22/2008CA2280773C Methods for the administration of amifostine
07/22/2008CA2268411C Bis(acridinecarboxamide) and bis(phenazinecarboxamide) as antitumour agents
07/22/2008CA2238661C Killer t cell activator and use thereof
07/22/2008CA2163805C Novel activating factor of leukocytes
07/17/2008WO2008086462A2 AMINO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF β-CANTENIN/TCF-4 PATHWAY AND CANCER TREATMENT AGENTS
07/17/2008WO2008086128A2 Aminopyrazole kinase inhibitors
07/17/2008WO2008086122A2 Imidazole derivatives as kinesin spindle protein inhibitors (eg-5)
07/17/2008WO2008086014A2 Bis-aryl amide derivatives useful for the treatment of cancer
07/17/2008WO2008086008A1 Method of treating multidrug resistant cancers
07/17/2008WO2008086005A1 Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof
07/17/2008WO2008086002A2 Slco1b3 genotype
07/17/2008WO2008085951A2 Treatment of tumors by ablating bone marrow-derived endothelial progenitor cells
07/17/2008WO2008085610A1 Use of iap inhibitors for the treatment of acute myeloid leukemia
07/17/2008WO2008084652A1 Vascular endothelial cell-binding peptide
07/17/2008WO2008084574A1 Anti-angiogenic agent
07/17/2008WO2008084496A1 Novel substituted 1h-benz [de] isoquinoline-1, 3 -diones
07/17/2008WO2008084261A1 Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
07/17/2008WO2008084241A2 Use of aminolevulinic acid and derivatives thereof
07/17/2008WO2008084106A1 Anti-kir antibodies, formulations, and uses thereof
07/17/2008WO2008084103A1 Combination treatment of solid cancers with antimetabolites and tyrosine kinase inhibitors
07/17/2008WO2008084081A2 2-substituted 5-phenylpyrimidines for the treatment of proliferative disorders
07/17/2008WO2008084040A1 Use of mage a3-protein d fusion antigen in immunotherapy combined with surgery, chemotherapy or radiotherapy for the treatment of cancer
07/17/2008WO2008083678A2 Pharmaceutically active compounds
07/17/2008WO2008083634A1 1-(2-deoxy-alpha-d-erythro-pentofuranosyl)-5-azacytosine for use as drug
07/17/2008WO2008083615A1 Complexes comprising angiostatin and its fragments, preparation preparing methods and uses thereof
07/17/2008WO2008083491A1 Compounds and method for treatment of cancer
07/17/2008WO2008055205A3 Pai-1 binding modulators for the treatment of ocular disorders
07/17/2008WO2008052187A3 Antibodies and immunoconjugates and uses therefor
07/17/2008WO2008044076A3 Therapy targeting cathepsin s
07/17/2008WO2008042282B1 Imidazole-4, 5-dicarboxamide derivatives as jak-2 modulators
07/17/2008WO2008039492A3 Crystalline forms of valrubicin and processes for their preparation
07/17/2008WO2008037716A3 Pharmaceutical compositions comprising nilotinib or its salt
07/17/2008WO2008030584A3 Indazole derivatives as modulators of interleukin- 1 receptor-associated kinase
07/17/2008WO2008023278A3 1alpha-hydroxy-2- (3 ' -hydroxypropylidene) -19-n0r- vitamin d compounds with a 1,1-dimethylpropyl side chain
07/17/2008WO2008021389A3 Using pi3k and mek modulators in treatments of cancer
07/17/2008WO2008016547A9 Aurora kinase inhibitors from an encoded small molecule library
07/17/2008WO2008010101A3 Antagonist antibody against epha2 for the treatment of cancer
07/17/2008WO2007097812A3 Therapeutic anti-her2 antibody fusion polypeptides
07/17/2008WO2001060998A9 Small oligonucleotides with anti-tumor activity
07/17/2008US20080171882 [(4S)-4-Methyl-2,5-dioxoimidazolidin-4-yl]methanesulfonyl chloride and [(4R)-4-methyl-2,5-dioxoimidazolidin-4-yl]methanesulfonyl chloride; chemical intermediates for enzyme inhibitors
07/17/2008US20080171874 Method for the regioselective preparation of substituted benzo[g]quinoline-3-carbonitriles and benzo[g]quinazolines
07/17/2008US20080171862 Double stranded RNA packaged in liposome for use therapeutic tool in treatment of cell proliferative and viral disorders; Antisense oligonucleotide for use in prevention and treatment of viral and tumor disorders; gene expression inhibition; RNA interference
07/17/2008US20080171861 Method and medicament for inhibiting the expression of a given gene
07/17/2008US20080171792 Administering aqueous sodium 4-phenylbutyrate to treat spinal muscular atrophy, central nervous system cancer, myelodysplastic syndrome, acute leukemia, glioblastoma multiforme, amyotrophic lateral sclerosis and colon cancer; cherry flavored liquid for children
07/17/2008US20080171782 2-[5-(3-Methylphenyl)-1-octyl-1H-indol-3-yl]acetamide (cysmethynil) and derivatives; anticarcinogenic agents; leukemia; antiinflammatory agents; multiple sclerosis, antiarthritic agents; rheumatic diseases;osteoporosis, stroke, asthma; glaucoma; screening; catalyzed CaaX protein methylation
07/17/2008US20080171778 N3 alkylated benzimidazole derivatives as mek inhibitors
07/17/2008US20080171773 A substantially pure enantiomer, (R)-5-Methyl-4,5-dihydro-pyrazole-1,5-dicarboxylic acid 1-[(4-chloro-phenyl)-amide] 5-{[2-fluoro-4-(2-oxo-2H-pyridin-1-yl)-phenyl]-amide}; controlling factor Xa proteolytic activity to prevent thrombosis with out the risk factors affecting diabetics, heart conditions, etc
07/17/2008US20080171769 Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
07/17/2008US20080171765 e.g. 1-[3-(acridin-9-ylamino)-5-hydroxymethylphenyl]-3-{4-[bis(2-chloroethyl)amino]phenyl}urea; anticarcinogenic agent; improved chemical stability and efficacy; brain tumor, breast cancer, colon cancer, leukemia, and neuroblastoma
07/17/2008US20080171763 Compounds and methods for treatment and prevention of diseases
07/17/2008US20080171758 Compounds and methods for the treatment of cancer
07/17/2008US20080171755 4-(4-Benzo[1,3]dioxol-5-yl-1H-pyrazol-3-yl)-2-methylpyrimidine; affinity for activin receptor-like kinases 4/5; potent antagonists of these Transforming Growth Factor beta family type receptors; fibrosis; anticarcinogenic and -metastasis agents; demelination; expression inhibited by reducing signal path
07/17/2008US20080171754 Certain pyrazoline derivatives with kinase inhibitory activity
07/17/2008US20080171747 Preparing 1-methyl,2-oxo,3-ethyl,4-cyclopentyl,6-chloro-1,2,3,4-tetrahydropteridine by reacting ethyl 2-N-cyclopentylaminobutyrate hydrochloride with 2,4-dichloro-5-aminopyrimidine; reducing, cyclizing and methylating by electrolytic substitution; antiproliferative, -carcinogenic and -tumor agents
07/17/2008US20080171744 Compounds and method for treatment of cancer
07/17/2008US20080171742 e.g. 6-methyl-2-{2-[3-(pyrid-2-yl)isoxazol-5-yl]pyrrolidin-1-yl}-4-(pyrid-2-ylamino)pyrimidine; insulin-like growth factor 1 receptor (somatomedin) antagonist; antiproliferative, antitumor, anticarcinogenic agent;
07/17/2008US20080171738 Administering a methylol-transferring antiproliferative agent taurolidine, taurultam or a mixture in dosing cycles of an administration phase of daily dose for 1-8days followed by a non-adminstration (rest) phase of 1-14 days; infusion; before or after suregical removal; antitumor, -carcinogenic agents
07/17/2008US20080171729 For an antiinflammatory agent, antiacne agent, antiproliferative agent, antiphototoxic agent, anti-hair loss agent, analgesic, antiaging agent, antiperspirant, antipruritic, astringent, or microbiocide; calcineurin inhibitors